Research Center for Functional Genomics, Biomedicine and Translational Medicine, The "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of Functional Sciences, Immunology and Allergology, The "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
J Cell Mol Med. 2021 Jan;25(1):591-595. doi: 10.1111/jcmm.15927. Epub 2020 Nov 19.
COVID-19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral-induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID-19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS-CoV-2 infection.
COVID-19 可呈现出多种临床特征，从无症状或轻微的呼吸道症状到暴发性急性呼吸窘迫综合征（ARDS）不等，具体取决于宿主的免疫反应和相关病理的程度。这意味着需要采取多种措施来限制病毒引起的重要器官病理损害导致的严重症状。阿片类药物主要因其镇痛作用而被广泛应用，但它们在缓解呼吸困难、免疫调节和溶酶体趋向性方面的应用可能代表了阿片类药物在 COVID-19 中的潜在用途。在这里，我们描述了这些潜在用途中的每一种所涉及的机制，强调了在治疗 SARS-CoV-2 感染引起的 ARDS 时使用阿片类药物的益处。
